AMGN · News · 20261104N

Revenue Performance and Mix

AMGEN INC · 2026-11-04 · Importance 37 · Surprise 32 · No source text

Q3 2026 total revenue increased 8% year over year to $10.4 billion, while product sales rose 8% to $9.88 billion, driven by higher volumes. Six key growth drivers grew 27% and accounted for more than 70% of product sales. Seventeen products achieved double-digit sales growth, although six blockbuster products recorded sales declines, including three with double-digit drops. Repatha sales rose 37% to $1.09 billion, supported by volume growth and U.S. new-to-brand prescriptions that increased more than 60%.

Key facts

• Amgen's Repatha sales increased 37% year over year to $1.09 billion, exceeding the Zacks Consensus Estimate of $1.04 billion. source
• Amgen's Repatha sales were $1.1 billion in Q3 2026, up 37% year over year. source
• Amgen product sales grew 8% year over year in Q3 2026; six key growth drivers grew 27% and represented over 70% of Q3 product sales. source
• Amgen's Q3 2026 total revenues increased 8% year over year to $10.37 billion, surpassing the consensus estimate of $9.95 billion. source
• Amgen product sales grew 8% to $9.88 billion in Q3 2026, driven by higher volumes; 17 products delivered double-digit sales growth during the quarter. source
• Amgen's Q3 2026 total revenues increased 8% to $10.4 billion. source
• Amgen's Q3 2026 total revenues grew 8% year over year to $10.4 billion. source
• Amgen's Q3 2026 total revenue increased over 8% to $10.37 billion. source

Impact estimates